34,699 Shares in Shattuck Labs, Inc. (NASDAQ:STTK) Purchased by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in Shattuck Labs, Inc. (NASDAQ:STTK) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 34,699 shares of the company’s stock, valued at approximately $121,000.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Shattuck Labs by 38.2% in the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after acquiring an additional 502,860 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Shattuck Labs in the 1st quarter worth $113,000. Bank of New York Mellon Corp increased its position in shares of Shattuck Labs by 209.7% during the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock valued at $857,000 after acquiring an additional 150,340 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in shares of Shattuck Labs by 15.0% during the 2nd quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company’s stock worth $2,314,000 after purchasing an additional 78,177 shares during the period. Finally, Ritholtz Wealth Management boosted its stake in Shattuck Labs by 57.4% in the second quarter. Ritholtz Wealth Management now owns 142,540 shares of the company’s stock valued at $550,000 after acquiring an additional 52,000 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Taylor Schreiber acquired 36,500 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were purchased at an average cost of $1.21 per share, for a total transaction of $44,165.00. Following the transaction, the chief executive officer now directly owns 71,002 shares of the company’s stock, valued at approximately $85,912.42. This trade represents a 105.79 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on STTK. Citigroup lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a report on Wednesday, October 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research note on Thursday, November 14th. Finally, HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a report on Friday, November 15th. Four research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to MarketBeat.com, Shattuck Labs has an average rating of “Hold” and a consensus price target of $8.67.

Shattuck Labs Trading Up 0.5 %

Shattuck Labs stock opened at $1.01 on Tuesday. Shattuck Labs, Inc. has a 12 month low of $0.94 and a 12 month high of $11.76. The stock has a fifty day simple moving average of $1.76 and a two-hundred day simple moving average of $3.77. The firm has a market cap of $48.22 million, a price-to-earnings ratio of -0.66 and a beta of 1.85.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.